Neratinib inhibited the kinase activity of EGFR, HER2, and HER4 in vitro at clinically relevant concentrations. Neratinib inhibited cell proliferation, HER2, and EGFR receptor phosphorylation; downstream MAPK and AKT signal transduction pathway activity and cell cycle regulatory pathway activities in HER2- and EGFR-dependent cancer cell lines.